[In-stent restenosis: which indications for drug-eluting stent?].
In-stent restenosis remains a limitation of stent implantation. Currently, at the exception of brachytherapy, any percutaneous technique is associated with a high recurrent restenosis rate (> 50%) in diffuse in-stent restenosis. Although based on a small number of patients, eluting stents (sirolimus, paclitaxel) appear promising for the treatment of instent restenosis.
Eltchaninoff
H
H
Service de cardiologie, hôpital Charles-Nicolle, 1, rue de Germont, 76031 Rouen, France. helene.eltchaninoff@chu-rouen.fr
Tron
C
C
Cribier
A
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D015906:Angioplasty, Balloon, Coronary; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D016503:Drug Delivery Systems; D004452:Echocardiography; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus